3rd Quarter - Report
PODESTA GROUP, INC. for COVIDIEN
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY 2012 appropriations legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ARANTHAN JONES | — |
Pharmacy PHA
Issues involving controlled substances and pain and addiction drugs. Issues related to acetaminophen.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIELE BAIERLEIN | — |
| ARANTHAN JONES | — |
| STEPHEN NORTHRUP | — |
| ANTHONY PODESTA | — |
| THOMAS B SPARKMAN | — |
Taxation/Internal Revenue Code TAX
International taxation on direct foreign investment.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIELE BAIERLEIN | — |
| ARANTHAN JONES | — |
Copyright/Patent/Trademark CPT
H.R. 1249 / S. 23, America Invents Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ARANTHAN JONES | — |
| THOMAS B SPARKMAN | — |
Health Issues HCR
Patient Protection and Affordable Care Act implementation. S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine. FDA approval process/510(k). Medical device tax.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIELE BAIERLEIN | — |
| ARANTHAN JONES | — |
| STEPHEN NORTHRUP | — |
| THOMAS B SPARKMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.